Table 2.
Conductance catheter measurements over time
| Parameter | Control (n = 8) | EPO±GCSF (n = 8) | t Testa |
|---|---|---|---|
| HR (bpm) | |||
| Baseline | 80 (3) | 86 (5) | NS |
| 1 Week post MIb | 83 (3) | 85 (4) | NS |
| 6 Weeks post MIb | 88 (5) | 92 (3) | NS |
| Repeated measures ANOVA (main effect) | NS | NS | |
| MAP(mmHg) | |||
| Baseline | 82 (4) | 85 (3) | NS |
| 1 Week post MIb | 80 (6) | 88 (4) | NS |
| 6 Weeks post MIb | 86 (8) | 85 (5) | NS |
| Repeated measures ANOVA (main effect) | NS | NS | |
| LVESP (mmHg) | |||
| Baseline | 86 (2) | 89 (5) | NS |
| 1 Week post MIb | 90 (4) | 93 (3) | NS |
| 6 Weeks post MIb | 76 (3)*, **** | 84 (4) | NS |
| Repeated measures ANOVA (main effect) | p < 0.02 | NS | |
| LVEDP (mmHg) | |||
| Baseline | 3.1 (0.3) | 2.9 (0.5) | NS |
| 1 Week post MIb | 9.9 (1.4)** | 8.8 (1.1)** | NS |
| 6 Weeks post MIb | 6 (0.5)*, **** | 4.3 (1.1)**** | NS |
| Repeated measures ANOVA (main effect) | p < 0.01 | p < 0.01 | |
| SV (mL) | |||
| Baseline | 28.6 (1) | 30.4 (0.7) | NS |
| 1 Week post MIb | 26.3 (1.5) | 25.7 (1.3)* | NS |
| 6 Weeks post MIb | 21.4 (0.7)**, **** | 27.7 (1.4) | p < 0.01 |
| Repeated measures ANOVA (main effect) | p < 0.01 | p = 0.03 | |
| Ees (mmHg/ml) | |||
| Baseline | 1.7 (0.2) | 1.4 (0.2) | NS |
| 1 Week post MIb | 1.2 (0.3) | 1.8 (0.3) | NS |
| 6 Weeks post MIb | 1.6 (0.3) | 1.7 (0.2) | NS |
| Repeated measures ANOVA (main effect) | NS | NS | |
| Vo intercept (ml) | |||
| Baseline | -37.2 (7) | -42.9 (10) | NS |
| 1 Week post MIb | -25.9 (6) | -28 (5) | NS |
| 6 Weeks post MIb | 11.4 (5)**, **** | -11 (6)** | p < 0.01 |
| Repeated measures ANOVA (main effect) | p < 0.01 | p < 0.01 | |
| PRSW (mmHg) | |||
| Baseline | 53 (3) | 51 (1) | NS |
| 1 Week post MIb | 41 (2)** | 40 (2)** | NS |
| 6 Weeks post MIb | 34 (1)**, *** | 41 (2)** | p < 0.05 |
| Repeated measures ANOVA (main effect) | p < 0.01 | p < 0.01 | |
| dP/dtmax(mmHg/s) | |||
| Baseline | 1270 (65) | 1255 (42) | NS |
| 1 Week post MIb | 1035 (53)** | 1020 (36)** | NS |
| 6 Weeks post MIb | 842 (38)**, **** | 1038 (20)** | p < 0.01 |
| Repeated measures ANOVA (main effect) | p < 0.01 | p < 0.01 | |
| dP/dtmin(mmHg/s) | |||
| Baseline | - 1156 (18) | -1168 (20) | NS |
| 1 Week post MIb | - 1024 (37)** | -1068 (23)** | NS |
| 6 Weeks post MIb | - 890 (30)**, **** | -1035 (21)** | p < 0.01 |
| Repeated measures ANOVA (main effect) | p < 0.01 | p < 0.01 | |
| τ (ms) | |||
| Baseline | 57 (1) | 56 (1) | NS |
| 1 Week post MIb | 69 (4)** | 64 (2)** | NS |
| 6 Weeks post MIb | 62 (1)*, *** | 56 (1)**** | p < 0.01 |
| Repeated measures ANOVA (main effect) | p < 0.01 | p < 0.01 | |
The values are expressed as the mean± by standard error (in parentheses)
HR heart rate, MAP mean arterial pressure, LVESP left ventricular end-systolic pressure, LVEDP left ventricular end-diastolic pressure, SV stroke volume, Ees linear end-systolic pressure-volume relation or end-systolic elastance, V 0 Volume zero Ees intercept, PRSW preload-recruitable stroke work, dP/dt max maximum rate of change of left ventricular pressure with time, dP/dt min peak of pressure decay, τ time constant of isovolumic relaxation, MI myocardial infarction
NS Non significant
aSignificance of differences “between groups” was tested by an unpaired t test
bChange from baseline value; significance of post-hoc test in repeated measures ANOVA design *p < 0.05 vs. baseline, **p < 0.01 vs. baseline, ***p < 0.05 vs. 1 week, ****p < 0.01 vs. 1 week